Objectives: We aim to further define the impact of the mechanism of fluoroquinolone resistance and inoculum load on the pharmacodynamic effects of levofloxacin and moxifloxacin on Streptococcus pneumoniae.
Introduction
Streptococcus pneumoniae is a significant cause of pneumonia, septicaemia, meningitis and community-acquired respiratory infections. Fluoroquinolone resistance in S. pneumoniae remains a relatively rare occurrence. The BSAC surveillance data for 2010-11 indicated that 90.3% of penicillin-non-susceptible S. pneumoniae isolates from the UK causing community-acquired pneumonia show intermediate resistance to ciprofloxacin (MIC .0.12 -2 mg/L) and 9.7% of isolates are fully resistant to ciprofloxacin (MIC .4 mg/L). 1 Resistance in S. pneumoniae is related to either mutation in the quinolone resistance-determining regions (QRDRs) of the genome or the presence of efflux pumps in the bacterial membrane. Fluoroquinolone resistance in S. pneumoniae is usually due to point mutations in the genes encoding both subunits of the target type II topoisomerase enzymes, topoisomerase IV (parC and parE) and DNA gyrase (gyrA and gyrB). Less frequently, mutations can be found in the genes parE and gyrB, encoding the B subunits of these proteins. In S. pneumoniae, first-step mutations in parC always precede those in GyrA. 2 DNA gyrase is the primary target for moxifloxacin; both topoisomerase IV (parC particularly) and DNA gyrase (gyrA) are targeted by levofloxacin. 3, 4 However, low-level resistance to fluoroquinolones can also be conferred by active efflux pumps mediated by pmrA or patA/B, which give rise to smaller increases in the MIC. 5, 6 Previously, several studies have suggested that efflux pumps are a requirement for the selection of fluoroquinolone resistance in S. pneumoniae. 7, 8 In addition, the overexpression of efflux pumps typically confers resistance to other antibacterial agents besides fluoroquinolones, such as some dyes, e.g. ethidium bromide, and detergents, e.g. SDS. Genes encoding efflux pumps are typically chromosomally encoded, ensuring mutations resulting in altered expression or function are retained in further generations in the absence of selective pressure or fitness cost.
The impact of these genotypic changes on fluoroquinolone MICs and pharmacodynamics has been extensively explored in pre-clinical animal and in vitro pharmacokinetic (PK) models. It is clear that these changes have a greater effect on some drugs than others (levofloxacin more than moxifloxacin or gemifloxacin) as well as being related to low AUC/MIC ratios. Studies have shown that 24 h free-drug AUC/MIC ratios of 30 -52 are required to eradicate S. pneumoniae from in vitro PK models and are associated with bacterial eradication and clinical efficacy in man; however, higher ratios may be required to prevent the emergence of resistance (EoR). 9 -14 The inoculum size may also be important in differentiating these agents in terms of their antibacterial effects against S. pneumoniae with defined fluoroquinolone resistance mechanisms.
To further define the impact of the mechanism of fluoroquinolone resistance on the pharmacodynamic effects of this drug class on S. pneumoniae, we compared the antibacterial effects of and EoR to moxifloxacin or levofloxacin for a panel of S. pneumoniae strains with a known mechanism of resistance, with efflux pumps or with mutations in the QRDRs, at high (10 8 cfu/mL) and low (10 6 cfu/mL) inocula.
Methods

In vitro model
A New Brunswick Bioflo 1000 in vitro model was used to simulate freedrug serum concentrations associated with the oral administration of 400 mg of moxifloxacin once daily, 750 mg of levofloxacin once daily or 500 mg of levofloxacin twice daily. The apparatus, which has previously been described, consists of a reservoir containing broth connected to a dosing chamber, which is in turn attached to a central chamber containing the bacteria. 15 The central chamber is connected to a collecting vessel for overflow. The contents of the dosing and central chamber were diluted with brain heart infusion broth using a peristaltic pump. The temperature was maintained at 36.58C.
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Strains
Five S. pneumoniae strains were used: 21843 (wild-type strain; moxifloxacin MIC of 0.38 mg/L and levofloxacin MIC of 1.5 mg/L); 21850 (efflux; moxifloxacin MIC of 0.38 mg/L and levofloxacin MIC of 0.75 mg/L); 21812 (parC mutation; moxifloxacin MIC of 0.5 mg/L and levofloxacin MIC of 1.5 mg/L); 37917 (gyrA and parC mutations; moxifloxacin MIC of 2 mg/L and levofloxacin MIC of 6 mg/L); and 21814 (gyrA and parC mutations; moxifloxacin MIC of 4 mg/L and levofloxacin MIC of 6 mg/L).
Bacterial killing curves
For all experiments, an initial inoculum of either 10 6 cfu/mL (low) or 10 8 cfu/mL (high) was used. The central chamber was sampled throughout the simulation at 0, 1, 2, 3, 4, 5, 6, 7, 12, 24, 25, 26, 27, 28, 29, 30, 31, 36, 48, 60, 72, 84 and 96 h to determine bacterial viable counts and drug concentrations. All PK simulations, killing curves and drug resistance determinations were performed at least in triplicate. The antibacterial effect was assessed by log change in viable count at 24, 48, 72 and 96 h. In addition, the area under the bacterial killing curve (log cfu/ mL . h) was calculated between 0-24 h and 0 -96 h.
EoR and determination of resistance mechanisms
EoR was assessed by plating aliquots at 0, 24, 48, 72 and 96 h onto blood agar plates containing either levofloxacin or moxifloxacin at 1×, 2× and 4× MIC. All antibiotics, dyes and efflux pump inhibitors (EPIs) were made up and used according to the manufacturer's instructions. The MIC of each antibiotic and dye (acriflavine and ethidium bromide) was determined for each strain by the standardized agar doubling dilution method according to BSAC guidelines. 16 The effect of the EPIs reserpine (20 mg/L) and sodium orthovanadate (50 mM) on the MIC of these agents was also measured. Synergy between reserpine or sodium orthovanadate and a fluoroquinolone or a dye was defined as a reduction in the MIC of the agent of more than two dilutions in the presence of the inhibitor. Isolates were defined as fluoroquinolone resistant if they were resistant to either levofloxacin (MIC .2 mg/L) or moxifloxacin (MIC .0.5 mg/L), according to EUCAST guidelines. Isolates were defined as dye resistant if the MIC of both dyes was two or more dilutions higher than for the control strain 21843 (MIC ≥4 mg/L for ethidium bromide and ≥8 mg/L for acriflavine). Isolates growing on the 2× and 4× MIC plates were classified into populations according to their phenotypic characteristics and dosing regimen; one representative from each population was subsequently molecularly characterized.
PCR and sequencing of QRDRs
One set of primers each specific for gyrA, gyrB, parC and parE was designed to amplify these genes for sequencing. The primer sets encompassed the QRDRs of gyrA (nt 137 to 408), gyrB (nt 1096 to 1553), parC (nt 104 to 465) and parE (nt 981 to 1334) (GenBank accession numbers: parC and parE, X95717; gyrA, X95718; and gyrB, Z67740). PCR was performed under the same conditions as described by Piddock et al. 6 The resulting amplimers were cleaned using the QIAquick PCR Purification Kit (Qiagen) and the products eluted in 30 mL of UltraPure distilled water (GIBCO TM ) and separated by 1% agarose gel electrophoresis (100 V for 35 min) before being quantified using Alpha Innotech software (AlphaEP) and Hyperladder 1 (NEB) as a quantification standard. The PCR sequencing reaction was performed using the BigDye w Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, UK) following the protocol outlined by the Functional Genomics Laboratory (Genetics, North Bristol NHS Trust). The sequences were read on an ABI Prism 3700 DNA analyser and data analysed using Chromas (Technelysium Pty Ltd; chromatogram evaluation) and the GeneDoc program tool (DNA-protein translation).
Results
Antibacterial effect
The target and simulated concentrations for moxifloxacin and levofloxacin were in agreement (data not shown). Against the wild-type strain, 21843, moxifloxacin produced rapid clearance from the model at the lower inoculum of 10 6 cfu/mL (Figure 1a ). At the higher inoculum of 10 8 cfu/mL, clearance was achieved at 24 h, with one simulation showing regrowth at 96 h ( Figure 1b) . The 750 mg of levofloxacin simulation also produced rapid clearance at the lower inoculum. However, at the higher inoculum there was a 5 log reduction in the bacterial count at 26 h, with regrowth to 10 7 -8 cfu/mL at 36 h; the bacterial count then remained static throughout the dosing regimen. The 500 mg of levofloxacin twice daily simulations also produced Comparative antibacterial effects of moxifloxacin and levofloxacin on S. pneumoniae rapid killing at 12 h at the lower inoculum, with the bacterial count fluctuating around the limit of detection (10 2 cfu/mL) for the remainder of the simulation (Figure 1a ). At the higher inoculum maximal bacterial killing was observed at 60 h (a 2 log reduction in viable count), at 72 h the viable counts increased to 10 7 -8 cfu/mL with both levofloxacin simulations ( Figure 1b ). Against strain 21850 (efflux), the moxifloxacin regimen resulted in clearance from the model at the lower inoculum by 24 h and at 60 h at the higher inoculum ( Figure 2a ). The levofloxacin simulations failed to produce clearance at either inoculum, but produced a 3 -4 log reduction in bacterial counts up to 30 h with the lower inoculum. Both levofloxacin regimens showed regrowth at 96 h (Figure 2a and b) . At the higher inoculum, a minimal reduction in the bacterial count was observed for the 750 mg of levofloxacin once daily dosing. The 500 mg of levofloxacin twice daily dosing showed maximal killing ( 2 log) at 60 h followed by regrowth.
Against strain 21812 (parC), none of the simulations generated clearance from the model at either inoculum (Figure 3a and b). With the low inoculum, moxifloxacin produced a 3 log drop in the viable count at 24 h with subsequent regrowth to 10 7 cfu/mL by 60 h (Figure 3a ). The 500 mg of levofloxacin twice daily simulation produced a 2.5 log reduction in the viable count; 750 mg of levofloxacin once daily was less potent, with a 1 log reduction in the viable count. Both levofloxacin regimens resulted in regrowth to 10 8 cfu/mL at 48 h. At the high inoculum, no antibacterial effect was observed with any of the regimens (Figure 3b) .
Against strain 37917 (gyrA and parC), at the low inoculum all three simulations produced immediate growth to reach a bacterial density of 10 8 cfu/mL at 24 h, which was maintained through to 96 h (Figure 4) . At the high inoculum, no antibacterial effect was seen for any of the simulations (Figure 4b ). In contrast, against strain 21814 (gyrA), moxifloxacin and 750 mg of levofloxacin once daily produced a 2-3 log reduction in the bacterial count at 12 h at the low inoculum; however, by 48 h the viable count was 10 7 -8 cfu/mL, which was maintained through to 96 h (Figure 5a ). At the high inoculum, no antibacterial effect was observed with any of the simulations (Figure 5b ).
EoR
No EoR at the low inoculum was noted with moxifloxacin or levofloxacin against the wild-type strain 21843 (Table 1) . At the high inoculum, EoR was observed with the 750 mg of levofloxacin once daily regimen on 7/8 occasions, but not with the 500 mg of levofloxacin twice daily regimen. Growth occurred on the 2× and 4× MIC plates (Table 2) .
Similarly, for strain 21850 (efflux), no EoR was noted for moxifloxacin at either inoculum (Tables 1 and 2 ). In contrast, at the low inoculum, growth was observed with 750 mg of levofloxacin once daily on the 2× MIC plates on 3/5 occasions; with 500 mg of levofloxacin twice daily, growth occurred on the 2× and 4× MIC plates (10 4 cfu/mL). At the high inoculum with 750 mg of levofloxacin once daily, growth was observed on the 2× and 4× MIC plates throughout the simulations (Table 2) . A similar pattern was observed with 500 mg of levofloxacin twice daily, with growth occurring on the 4× MIC plates at 96 h on 1/3 occasions and 3/3 occasions on the 2× MIC plates.
EoR was noted with all regimens at both inocula for the 21812 parC strain. At the low inoculum, all three regimens had growth of 10 7 -8 at 96 h. At the high inoculum, 750 mg of levofloxacin suppressed the amount of resistance on the 2× and 4× MIC plates to 10 2 -3 cfu/mL; for moxifloxacin and 500 mg of levofloxacin the bacterial counts were 10 3 -4 cfu/mL on the 4× MIC plates. Both levofloxacin regimens produced growth on the 2× MIC plates at both inocula for the gyrA and parC-containing strain 21814, with bacterial counts of 10 6 -8 cfu/mL (Tables 1 and 2 ). No growth occurred on the 4× MIC plates. Moxifloxacin did not result in EoR. In contrast, strain 37917 only produced growth on the 2× MIC plates on 1/3 and 1/4 occasions for 500 and 750 mg of levofloxacin, respectively, at the high inoculum (Table 2) . Neither inoculum level produced resistant mutants with the moxifloxacin regimen.
Determination of resistance mechanisms
Any emerging resistant strains that were defined as fluoroquinolone resistant and/or dye resistant had their QRDRs of the topoisomerase genes gyrA, gyrB, parC and parE sequenced to identify any mutations within these regions. Any emerging resistant strains, from a particular parent strain, with the same susceptibilities and same QRDRs were grouped into populations and are shown in Table 3 .
In the wild-type strain, 21843, the 750 mg of levofloxacin once daily dosing regimen alone selected for two different resistant populations. The first population had a fluoroquinoloneand dye-resistant (FQDR) phenotype (levofloxacin only and dye resistant) with QRDR mutations in parC at D78A and K137N. A ≥8-fold increased susceptibility was observed on the addition of the EPI reserpine to levofloxacin and the dyes. The second population was fluoroquinolone resistant with a QRDR mutation in parC at S79F and a gyrA mutation at S81F. This population contained a gyrA mutation leading to decreased susceptibilities to both levofloxacin and moxifloxacin. The addition of reserpine had no effect on the MIC of levofloxacin or moxifloxacin.
In strain 21850, which possesses an efflux resistance mechanism, both levofloxacin dosing regimens (500 and 750 mg) produced strains able to grow on 2× MIC plates. The moxifloxacin dosing regimen did not select for mutants. Two phenotypic populations, a population resistant to dyes only and an FQDR population, were selected from the levofloxacin regimens. In the dye-resistant population, there were no QRDR mutations and the phenotype was identical to the parent strain (21850), with no change in the MICs observed. The second population was FQDR, containing a QRDR mutation in gyrA at S81F and in parC at S79Y. A ≥8-fold decreased susceptibility was observed for moxifloxacin and levofloxacin, respectively. A 4-fold decreased susceptibility was observed for both dyes. A ≥4-fold increased susceptibility was observed on the addition of reserpine to levofloxacin and the dyes.
In the FQDR strain 21812, with a known mutation in parC (K137N), all three dosing regimens selected for mutants. Three phenotypic populations, which were all FQDR, were selected from the dosing regimens. The first population had an identical phenotype to the parent strain, with no new mutations within the QRDRs. A ≥4-fold increased susceptibility was observed on the addition of reserpine to levofloxacin and the dyes. In the second population, a 4-fold decreased susceptibility to levofloxacin and moxifloxacin compared with the parent strain was observed. Strains in this population also contained four QRDR mutations: S81F in gyrA, K137N in parC and I460V and D435N in parE. Lastly, in the third population, a 2-and 4-fold decreased susceptibility to levofloxacin and the dyes, respectively, compared with the parent strain was observed. No new mutations within the QRDRs were identified; however, a ≥4-fold increased susceptibility was observed on the addition of reserpine to levofloxacin and the dyes.
In the FQDR strain 21814, with known QRDR mutations in gyrA (S81Y) and parC (S79F), all three dosing regimens selected for mutants. Two phenotypic populations, which were all FQDR, were selected from the dosing regimens. The first population had a 2-fold decreased susceptibility to levofloxacin and the dyes compared with the parent strain and also contained three QRDR mutations: S81Y in gyrA, S79F in parC and I460V in parE. A ≥8-fold increased susceptibility was observed on the addition of reserpine to levofloxacin and the dyes. The second population had no new mutations within the QRDRs and had an identical phenotype to the parent strain.
In the fluoroquinolone-resistant strain 37917, with known QRDR mutations in gyrA (S81F) and parC (S79F), only one phenotypic population, which was fluoroquinolone resistant, was selected from the levofloxacin dosing regimens. The strains in the population had an identical phenotype to the parent strain; the MICs of levofloxacin and acriflavine were unaffected by the addition of reserpine (Table 3) . No mutants were selected from the moxifloxacin dosing regimen, even though 37917 possessed the same QRDR mutations in gyrA and parC as the parent strain (21814) used in the study, where the moxifloxacin regimen did select for a mutant population. It should be noted that 21814 was FQDR, whereas 37917 was only fluoroquinolone resistant. 17 
Discussion
The data presented here indicate that bacterial inoculum and mechanism of resistance, in addition to MIC and drug exposure, determine the antibacterial effect of and risk of resistance to moxifloxacin and levofloxacin in S. pneumoniae. Strains with a moxifloxacin MIC ,0.5 mg/L and levofloxacin MIC ,1.5 mg/L have markedly different patterns of antibacterial effect and risk of EoR, depending on the underlying mechanism (none, efflux or parC). However, strains with a moxifloxacin MIC of ≥2 mg/L or levofloxacin MIC of 6 mg/L (37917 and 21814 gyrA and parC mutations) showed a poor antibacterial effect and low risk of increased resistance.
The higher inoculum resulted in a reduced antibacterial effect for the wild-type/efflux strains. The 750 mg of levofloxacin once daily regimen at both the high and low inocula produced mutations in gyrA and parC, increasing MICs of both levofloxacin and moxifloxacin.
The higher drug exposure of 500 mg of levofloxacin twice daily (AUC/MIC ratio of 112) was insufficient to prevent fluoroquinolone-resistant mutants in the efflux strain. This is in agreement with in vitro model data from Odenholt et al., 14 which showed that an AUC/MIC ratio of 100 produced maximal antibacterial effect for both maxifloxacin and levofloxacin but did not eradicate wild-type, parC and gyrA and parC-containing S. pneumoniae. LaPlante et al., 16 comparing gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin, observed that increasing the fAUC/MIC against two wild-type strains delayed the first-and second-step mutations for gemifloxacin, gatifloxacin and moxifloxacin. However, levofloxacin fAUC/MICs of ≤86 and 82 led to first-step parC and second-step gyrA mutations in fluoroquinolone susceptible strains, respectively; a moxifloxacin fAUC/MIC of 31 prevented such mutations. This is in accordance with our study; levofloxacin 750 mg once daily simulations, with an AUC/MIC ratio 42 against the wild-type, produced gyrA and parC mutations and efflux pump overexpression.
It would appear likely that an efflux pump was present in strain 21814. This strain had raised baseline MICs of acriflavine and ethidium bromide, which were significantly reduced in the presence of reserpine. Levofloxacin MICs were also affected by the addition of reserpine, implying that an efflux-related mechanism of resistance is mediated. The data here support a role for efflux in levofloxacin resistance and confirm data from Madaras-Kelly et al., 18 who observed that the presence of efflux pumps reduced the antibacterial effects of levofloxacin, moxifloxacin and sparfloxacin against S. pneumoniae and promoted the EoR. Their data also showed that moxifloxacin exhibited a greater antimicrobial effect than levofloxacin against Comparative antibacterial effects of moxifloxacin and levofloxacin on S. pneumoniae efflux and non-efflux strains. In contrast, Avrain et al. 19 showed that exposing S. pneumoniae to subinhibitory concentrations of ciprofloxacin resulted in patA/B-mediated efflux, regardless of pmrA expression; they suggested that levofloxacin and moxifloxacin activity would be less affected. This is in accordance with Jumbe et al., 20 who demonstrated that exposure to ciprofloxacin generated clones that allowed overexpression of a reserpine-responsive pump without changes in the parC/E or gyrA/B target sites.
In this study, efflux appears to be a prerequisite for levofloxacin and dye resistance, as demonstrated by strains 21843 (wildtype), 21850, 21812 (parC) and 21814 (parC and gyrA). Louie et al., 21 using ciprofloxacin and levofloxacin, had previously postulated that the induction of efflux pumps allows time for the production of target site mutations in gyrA and parC, even when the bacterial population was below the reciprocal of the mutation frequency. Removal of the drug would enable downregulation of the pump, resulting in an isolate with a target site mutation without stable overexpression of efflux pumps. Our data confirm this; the wild-type and strains with known resistance mechanisms all showed efflux pump overexpression after exposure to levofloxacin.
We were able to show that levofloxacin dosing selects for moxifloxacin resistance, as occurred with both the wild-type and efflux strains; on each occasion a mutation in gyrA was noted, suggesting that the gyrA mutation is required for moxifloxacin resistance. The data here also show moxifloxacin to be more effective at preventing mutations; moxifloxacin only generated phenotypic resistance against strains that were known to have parC and gyrA mutations. Li et al. 22 showed that moxifloxacin was 4-to 10-fold more effective at restricting resistant mutants when compared with levofloxacin. The selection frequency for topoisomerase mutants was 1000 times lower than with levofloxacin; however, this frequency was lost when secondstep mutants were selected. This was seen in our model, where levofloxacin produced both dye-resistant and fluoroquinoloneresistant mutants with increased moxifloxacin MICs from the wild-type and efflux strains. In contrast, moxifloxacin did not select for resistant mutants. It has been proposed that these differences in propensity for resistance development may be due to moxifloxacin's methoxy moiety at the C-8 position. 23 In contrast, De Vecchi et al. 24 reported that levofloxacin and moxifloxacin showed an equivalent mutation rate ,10 11 at plasma peak concentrations of 5.29, 19.8 and 3.23 mg/L (500 and 750 mg of levofloxacin and 400 mg of moxifloxacin, respectively). In their study, only parC mutations were found for levofloxacin.
In conclusion, these data confirm that levofloxacin dosing regimens with low AUC/MICs select for efflux pump overexpression, which leads to fluoroquinolone resistance. Increased inoculum also has an important role in the expression of such resistance. Furthermore, levofloxacin dosing may select for gyrA mutations, inducing moxifloxacin resistance. Moxifloxacin showed greater antibacterial effect and less risk of EoR than levofloxacin against these strains with defined resistance mechanisms. These data confirm that a fluoroquinolone AUC/ MIC ratio of .100 is required for the prevention of EoR.
